title: Evaluation of meloxicam for the treatment of obstructive feline idiopathic cystitis.
abstract: Objectives The aim of the study was to investigate the effect of the non-steroidal anti-inflammatory drug meloxicam on the clinical course of obstructive idiopathic cystitis in cats in a placebo-controlled clinical study. Methods Thirty-seven cats with obstructive idiopathic cystitis were enrolled. Cats received supportive treatment and an indwelling transurethral catheter for 48 h. On days 0 and 1, all cats received buprenorphine 0.01 mg/kg subcutaneously every 8 h. On day 1, cats were randomly assigned to the meloxicam (n = 18) or placebo group (n = 19) and received meloxicam (0.1 mg/kg on day 1, 0.05 mg/kg on days 2-5) or placebo orally for five consecutive days. Cats were monitored by repeated physical examinations and urinalysis, and with a 5 day questionnaire filled in by the owners after discharge and a telephone interview 3 months after presentation. Parameters for evaluation of treatment success were the occurrence of recurrent urethral obstruction, results of physical examinations and questionnaires. Results Recurrent urethral obstruction occurred in 4/18 cats (22%) in the meloxicam group and 5/19 cats (26%) in the placebo group ( P = 1.000). General demeanour and pain on abdominal palpation during hospitalisation improved significantly in both groups ( P <0.001). After discharge, with regard to general demeanour, food intake and voiding behaviour, there were no significant differences within or between groups at different time points. Conclusions and relevance Orally administered meloxicam for 5 days did not influence the incidence of recurrent urethral obstruction and the recovery from clinical signs in cats with obstructive feline idiopathic cystitis. The persistence of clinical signs in most of the cats 1 week after initial presentation indicates that symptomatic treatment for a longer period of time is warranted.
authors.affiliation: 1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.
authors.forename: Roswitha
authors.initials: R
authors.lastname: Dorsch
authors.affiliation: 1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.
authors.forename: Friederike
authors.initials: F
authors.lastname: Zellner
authors.affiliation: 1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.
authors.forename: Bianka
authors.initials: B
authors.lastname: Schulz
authors.affiliation: 2 Clinic for Ruminants, LMU University Munich, Munich, Germany.
authors.forename: Carola
authors.initials: C
authors.lastname: Sauter-Louis
authors.affiliation: 1 Clinic of Small Animal Medicine, LMU University Munich, Munich, Germany.
authors.forename: Katrin
authors.initials: K
authors.lastname: Hartmann
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D002415:Cats; D003556:Cystitis / Q000188:drug therapy / Q000662:veterinary*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D000077239:Meloxicam; D010067:Ownership; D010146:Pain / Q000188:drug therapy / Q000662:veterinary*; D010147:Pain Measurement / Q000662:veterinary; D011795:Surveys and Questionnaires; D013843:Thiazines / Q000008:administration & dosage / Q000627:therapeutic use*; D013844:Thiazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014524:Urethral Obstruction / Q000188:drug therapy / Q000662:veterinary*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam